- 期刊Complementary therapies in medicine（Complement Ther Med）
- 发表时间2026-10-17
- 作者Khongphakdee P, Jumnianpol J, Puttarak P, Sawangjit R, Sae-Tan S
- 卷期页码103453
- 文献类型Review
- DOI10.1016/j.ctim.2026.103453
- PMID42892340
摘要机译
糖尿病前期是一个日益增长的全球健康问题，与糖尿病和心血管疾病的高风险相关。姜黄素已被研究血糖、脂质和炎症效应，但不同制剂的比较数据仍然有限。该网络荟萃分析（NMA）评估了糖尿病前期成年人的姜黄和姜黄素制剂。
在七个数据库中搜索了比较姜黄/姜黄素制剂和安慰剂的随机对照试验（RCT）。主要结果包括血糖、脂质和炎症标志物。两名评价者独立提取数据并评估偏差风险。进行了累积排名曲线（SUCRA）下表面的NMA。24项随机对照试验（25篇出版物，1,952名参与者；平均基线空腹血糖（FBS）：
110.3mg/dL）评估了八种基于姜黄素的制剂。姜黄提取物与其他化合物（EC）和姜黄提取物（E）相结合，与大规模杀伤性武器-10.73（95%置信区间：-14.22，-7.25；SUCRA 92.2%）和-10.57（95%置信区间：-14.35，-6.79；91.5%；SUCRA 91.5%）的FBS显著降低相关。E与HbA1c的显著降低相关，而EC与MWD-0.73的HOMA-IR降低相关（95%置信区间：
-1.41，-0.05；SUCRA 79.8%）。全姜黄与其他化合物（WC）与LDL-C显著降低相关（WMD：-37.19,95%CI：-56.97，-17.42；SUCRA：97.3%）。E与较低的2型糖尿病发病风险相关（RR=0.05；95%CI：0.00,0.78），尽管这一估计是基于证据的低确定性。炎症标志物没有观察到显著影响。
由于异质性和试验持续时间短，以及组合制剂之间的可变性，证据的总体确定性较低。在糖尿病前期，观察到formulation-specific代谢效应。然而，鉴于证据的低确定性，这些发现应谨慎解释，并在更大、更长期的试验中得到证实，然后才能做出临床推荐。
展开英文摘要原文
Prediabetes is a growing global health concern associated with higher risk of diabetes and cardiovascular disease. Curcumin has been studied for glycemic, lipid, and inflammatory effects, but comparative data across formulations remain limited. This network meta-analysis (NMA) evaluated turmeric and curcumin formulations in adults with prediabetes. Seven databases were searched for randomized controlled trials (RCTs) comparing turmeric/curcumin formulations with placebo. Primary outcomes included glycemic, lipid, and inflammatory markers. Two reviewers independently extracted data and assessed risk of bias. NMAs with surface under the cumulative ranking curve (SUCRA) were performed. Twenty-four RCTs (25 publications, 1,952 participants; mean baseline fasting blood sugar (FBS): 110.3mg/dL) evaluating eight curcumin-based formulations were included. Turmeric extract combined with other compounds (EC) and turmeric extract (E) were associated with significant reductions in FBS with WMD -10.73 (95%CI: -14.22, -7.25;SUCRA 92.2%), and -10.57 (95%CI: -14.35, -6.79;91.5%;SUCRA 91.5%), respectively. E was associated with a significant reduction in HbA1c, while EC was associated with lower HOMA-IR with MWD -0.73 (95%CI: -1.41, -0.05; SUCRA 79.8%). Whole turmeric with other compounds (WC) was associated with a significant reduction in LDL-C (WMD: -37.19, 95%CI: -56.97, -17.42; SUCRA: 97.3%). E was associated with a lower risk of incident type 2 diabetes (RR= 0.05; 95%CI:0.00,0.78), although this estimate was based on low-certainty of evidence. No significant effects were observed for inflammatory markers. Overall certainty of evidence was low due to heterogeneity and short trial durations, and variability among combination formulations. In prediabetes, formulation-specific metabolic effects were observed. However, given the low certainty of evidence, these findings should be interpreted cautiously and confirmed in larger, longer-term trials before clinical recommendation can be made.
相关物质
本页由系统自动抓取 PubMed 元数据生成；标题与摘要版权归原作者与期刊所有；机译内容仅供参考，请以英文原文为准；收录不代表本站观点，亦不作为用药或医疗建议。